Pan Cancer T announces that Dr. Helen Tayton-Martin has joined its board as an independent director
Dr. Helen Tayton-Martin joins our board, bringing decades of leadership in TCR-T cell therapy and biotech growth.
Pan Cancer T’s potential recognised at MEET2WIN with two awards
June 15, 2025
On 5th-7th May, Pan Cancer T’s CEO, Rachel Abbott, attended the 10th edition of MEET2WIN, the European partnering convention dedicated to the fight against cancer. Organised by the French platform MATWIN (a 100% subsidiary of Unicancer), the event brought together more than 300 international stakeholders – researchers, major groups, biotechs, startups, investors, and support organizations – united by a shared ambition: to accelerate innovation in oncology.
Pan Cancer T was recognised with the Best Investment Potential award by the OUI (Oncology Upward Investment) jury, composed of around 15 European investors.
Additionally, Pan Cancer T received an award from the QUICK PITCH jury, composed of MATWIN board members and the full MEET2WIN audience. This gave Rachel the opportunity to give a more extensive presentation and receive feedback from the
prestigious MATWIN international board, comprising Oncology R&D decision-makers from academic experts from leading European cancer research centres and the 14 partner pharma companies (Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Exact Sciences, GlaxoSmithKline, insitro, MSD, Pierre Fabre, Pfizer, Sanofi, Servier, and Takeda).
Other news
Extended Partnership with NecstGen
Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
4.25 Million in Seed Extension Round
Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round.
Pan Cancer T are EIT Health Catapult Finalists
On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich.
Awarded the Seal of Excellence from the European Commission
Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence.
Selected as semi finalist of the EIT Health Catapult venture challenge
Pan Cancer T has been selected as semi finalist of the EIT Health Catapult venture challenge
Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Poster Presentation
Pan Cancer T is presenting preclinical data at CIMT and SITC 2023
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
“I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini. “T cell therapies hold tremendous promises for tumor patients and the development of TCR T therapies is just gaining momentum. I am convinced that Pan Cancer T will play a pioneering role in this field, as the Company is working on the main challenges in the field: identifying novel tumor antigens and leveraging engineering technology to enhance the T cells´ durability.”
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
Expanded investor syndicate strengthens the company’s financial position and investor base